ClinicalTrials.gg
Enrolling by invitationNCT06701201Updated Aug 4, 2026

A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product

An observational study in Cancer, sponsored by Verismo Therapeutics. Enrolling by invitation at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Verismo Therapeutics · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this study is to monitor potential long-term risks associated with the administration of SynKIR CAR T cell products.

Read the detailed description

This is a study for the Long Term Follow Up for all participants treated with Verismo Therapeutics' SynKIR CAR T cell products in accordance with regulatory guidance. The primary objective of this study is to monitor the long-term safety of SynKIR CAR T cell products.

No investigational product will be administered in this LTFU study. Eligible participants must have received at least 1 infusion of a SynKIR CAR T cell product under a Verismo Therapeutics parent protocol. Participants will be invited to enroll into this LTFU study after either early discontinuation from or completion of the parent protocol.

In accordance with regulatory guidelines, this study will follow participants for a period of 15 years following infusion of Verismo Therapeutics' SynKIR CAR T cell product, to monitor for delayed adverse events (AEs), detection of replication competent lentivirus (RCL), and to assess long-term efficacy and persistence of gene-modified T cells.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Cancer
  • CAR-T
  • CAR-T Cells
  • KIR-CAR
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 60 is below the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Verismo Therapeutics is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible participants must have received at least 1 infusion of a SynKIR CAR T cell product in a Verismo Therapeutics parent protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. All adult participants who have received any amount of SynKIR CAR T cell product in a study sponsored by Verismo Therapeutics.
  2. Participant is willing and able to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

There are no specific exclusion criteria.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • SynKIR-110

    Participants who previously received SynKIR-110 in an interventional trial

    Drug: SynKIR-110

  • SynKIR-310

    Participants who previously received SynKIR-310 in an interventional trial

    Drug: SynKIR-310

Interventions

  • DrugSynKIR-110

    Autologous T cells Transduced with Mesothelin KIR-CAR

  • DrugSynKIR-310

    Autologous T Cells transduced with CD19 KIR-CAR

06

What researchers measure

Primary outcomes

  1. To monitor the long-term safety of participants that have been infused with a SynKIR CAR T cell product

    Frequency and severity of delayed AEs considered related to SynKIR CAR T cell product

    Time frame: Up to 15 years from SynKIR CAR T cell product administration

  2. To monitor the long-term safety of participants that have been infused with a SynKIR CAR cell product

    Presence of RCL VSV-G DNA

    Time frame: Up to 15 years from SynKIR CAR T cell product administration

Secondary outcomes

  1. To assess the long-term clinical efficacy of SynKIR CAR T cell product

    Overall survival

    Time frame: Up to 15 years from SynKIR CAR T cell product administration

  2. To assess the long-term clinical efficacy of SynKIR CAR T cell product

    Progression-free survival

    Time frame: Up to 15 years from SynKIR CAR T cell product administration

  3. To assess the persistence of SynKIR-modified T cells

    Presence of a SynKIR CAR DNA sequence

    Time frame: Up to 15 years from SynKIR CAR T cell product administration

07

Study locations

7 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2042, 205 months after the start.

Of 148 industry-sponsored observational studies under Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 102. This study's planned 205 months is above that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 22, 2024
StartActual
Jan 27, 2025
Primary completionEst.
Feb 2042
CompletionEst.
Feb 2042
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06701201
Lead sponsor
Verismo Therapeutics
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Jan 27, 2025
Primary completion
Feb 2042 (estimated)
Completion
Feb 2042 (estimated)
Last update
Aug 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion